Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | PDE8B | O95263 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20149612 | 0.90 | RET (0.38) | RETPDE8BDRD2HTR2AHRH1 | |
| SCHEMBL20070798 | 0.83 | RET (0.39) | RETPDE8BDRD2HTR2AHRH1 | |
| SCHEMBL20148668 | 0.80 | RET (0.41) | RETPDE8BDRD2HTR2AHRH1 | |
| SCHEMBL20070790 | 0.73 | ALDH1A1 (0.43) | RET | |
| SCHEMBL23126230 | 0.73 | RET (0.35) | RETSLC6A3 | |
| SCHEMBL20149631 | 0.71 | RET (0.39) | RET | |
| SCHEMBL22812208 | 0.71 | RET (0.39) | RET | |
| SCHEMBL20149605 | 0.70 | RET (0.40) | RET | |
| SCHEMBL22030854 | 0.69 | ALDH1A1 (0.44) | RET | |
| SCHEMBL21159001 | 0.68 | ALDH1A1 (0.42) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | RET 1/4885PDE8B 511/4885DRD2 3397/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885PDE8B 511/4885DRD2 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.